Dalfampridine (Ampyra®) is the first oral agent approved by the FDA for the treatment of Multiple Sclerosis (MS) symptoms. Dalfampridine is not a disease modifying therapy (DMT) for MS but targets functional motor impairment. It has the potential to improve walking ability and strengthen the lower leg in people with MS. This may provide patients with the ability to stay independent for longer periods of time and improve quality of life. Dalfampridine is broadly classified as a potassium-channel blocker. When the myelin sheath is damaged, potassium may become too active, causing a decrease in nerve function. Dalfampridine blocks potassium from entering the channel, thereby decreasing the disruptions in conduction along the nerves that are associated with functional motor impairment. Dalfampridine is associated with serious adverse events. It appears to have dose related adverse events, perhaps the most serious is an increase in MS relapse and of seizures. Individuals who have questions about dalfampridine (Ampyra®) should contact their healthcare provider.
For more information:
Articles:Dalfampridine (Ampyra®): Criteria for Use January 2013
Patient website: http://www.moveoverms.org/
This easy to use, 9-page flip book addresses the impact of walking difficulty, assessment with the EDSS, MSWS-12, 25-foot walk, and TUG test.
The authors are affiliated with the Mellen Center for MS Treatment and Research, Neurologic Institute, Cleveland Clinic Foundation, Cleveland, Ohio. The 8" x 5" compact handbook clearly addresses the pathology and pathogenesis of MS, clinical features, diagnosing, treatment of relapses, disease modifying therapies, symptom management and medical management of patients including multidisciplinary care and health maintenance.
If you would like a copy of either of these resources, please contact email@example.com
Date Posted: July 2, 2012